Investing.com -- The Danish krone experienced a dip following disappointing clinical trial results from Denmark's pharmaceutical giant, Novo Nordisk (NYSE: NVO) A/S. The results have raised concerns ...

After a stunning 703% run-up in price over the past five years, shares of Eli Lilly and Co. have been on a roller-coaster ...

Novo Nordisk posts disappointing update related to its new weight loss drug CagriSema. Novo Nordisk stock is now down 25% ...

Denmark’s usually-stable currency was left weakened on Friday after the news that pharmaceutical giant Novo Nordisk, a major ...

Novo Nordisk A/S posted the largest decline among large stocks ... Electrolux AB Series A rounded out the top three leaders on Friday, with shares gaining 5.1%. In Denmark, the OMX Copenhagen 20 Index ...

Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly ...

Shares in Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, plunged ...

Novo Nordisk (NVO) released mixed clinical-trial results for its potential Ozempic successor on Friday, leaving Wall Street ...

Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of ...

Novo traded down more than 20% Friday morning, its biggest loss since 2002. The CagriSema news boosted competitors, such as ...

The Danish crown weakened on Friday, after disappointing results from a late-stage trial of a new weight-loss drug drove a ...